T-cell Engager Market (2026 - 2033)

T-cell Engager Market Summary

The global t-cell engager market size was valued at USD 5.0 billion in 2025 and is projected to grow from USD 6.6 billion in 2026 to USD 14.5 billion by 2033, at a CAGR of 11.9% from 2026 to 2033. The market in North America dominated with a revenue share of 74.1% in 2025. Market growth is driven by the increasing adoption of immunotherapies for cancer treatment, rising demand for targeted therapies, and advancements in bispecific antibody engineering. Growing clinical research into T-cell engagers for hematological malignancies and solid tumors, along with expanding investments in oncology drug development, is further supporting market growth.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

To learn more about this report, Download Free Sample Report

Market Dynamics

The T-cell engager market is experiencing significant growth, driven by rising investments in cancer immunotherapy, advances in bispecific antibody engineering, and an expanding clinical pipeline of targeted immunotherapies. Growing research into T-cell engagers for hematological malignancies and solid tumors, coupled with increasing focus on novel antigen targets, combination therapies, and next-generation engager platforms, is expected to expand therapeutic applications and improve treatment outcomes, thereby creating new opportunities for market growth.

Market Concentration & Characteristics

The T-cell engager industry is highly innovative, driven by advances in bispecific and multispecific antibody engineering, novel tumor antigen targeting, and conditional T-cell activation technologies. Companies are increasingly developing therapies designed to improve tumor selectivity, enhance T-cell activation, and address limitations associated with existing immunotherapies, particularly in solid tumors. For instance, in June 2025, Johnson & Johnson reported early clinical findings for pasritamig, a bispecific T-cell engager targeting KLK2 in advanced prostate cancer, highlighting ongoing efforts to expand treatment options for solid tumors.

“These first-in-human results for pasritamig are highly encouraging, demonstrating that KLK2 is a viable target for T-cell engagers in metastatic castration-resistant prostate cancer.”

- Capucine Baldini, M.D., Ph.D., Drug Development Department (DITEP), Institut Gustave Roussy, and presenting author

The T-cell engager industry is experiencing moderate M&A activity, as pharmaceutical companies seek to strengthen their immunotherapy pipelines and access differentiated T-cell engager technologies. These transactions enable companies to expand their therapeutic portfolios, access innovative drug candidates, and accelerate clinical development across oncology and other indications. For instance, in March 2026, Gilead Sciences announced an agreement to acquire Ouro Medicines, adding gamgertamig, an investigational BCMA × CD3 T-cell engager being developed for autoimmune diseases, to its pipeline. This transaction highlights the growing strategic interest in extending T-cell engager technologies beyond oncology.

“This acquisition underscores our commitment to advancing transformative therapies for people living with serious autoimmune diseases. BCMA is a validated target with emerging data demonstrating potentially transformative outcomes in autoimmune diseases. BCMA targeted T cell engagers represent a differentiated approach with the potential to induce durable disease control. This novel framework complements our expanding inflammation pipeline and reflects our strategy to invest in innovative science that may redefine standards of care.”

- Dietmar Berger, MD, PhD, Chief Medical Officer of Gilead

To learn more about this report, Download Free Sample Report

The T-cell engager market is influenced by stringent regulatory requirements related to clinical efficacy, treatment safety, manufacturing quality, and post-marketing monitoring. Regulatory evaluation focuses on demonstrating meaningful clinical benefits while managing risks such as cytokine release syndrome and immune-mediated neurological toxicities. For instance, in November 2025, the U.S. FDA granted traditional approval to Amgen's Imdelltra (tarlatamab-dlle) for extensive-stage small-cell lung cancer. This milestone highlights the role of clinical evidence and safety management in supporting the commercialization of T-cell engager therapies.

The T-cell engager industry is experiencing rapid expansion through the development of T-cell engagers targeting emerging cancer-associated antigens and previously underserved solid tumors. Developers are exploring new molecular targets and antibody formats to broaden treatment applications and address limitations associated with existing therapies. For instance, in April 2025, Context Therapeutics dosed the first patient in a Phase I clinical trial of CT-95, a mesothelin × CD3 T cell engaging (“TCE”) bispecific antibody being investigated for mesothelin-expressing cancers. Such developments reflect continued efforts to expand the therapeutic pipeline and diversify product offerings across cancer indications.

 The T-cell engager industry is witnessing a moderate to high regional expansion, driven by the growing adoption of advanced cancer immunotherapies, increasing participation in multinational clinical trials, and rising investments in targeted drug development. Pharmaceutical and biotechnology companies are expanding their research and development activities across established and emerging markets to advance clinical pipelines, improve patient access, and support the commercialization of novel T-cell engager therapies.

Analyst Perspective

The T-cell engager market is expected to witness significant growth, driven by increasing demand for targeted immunotherapies and expanding research into bispecific antibodies for hematological malignancies and solid tumors. Growing investments in oncology drug development, advancements in antibody engineering, and the expanding clinical pipeline are supporting market expansion. Moreover, increasing regulatory approvals and strategic collaborations among biopharmaceutical companies are expected to accelerate the development and commercialization of novel T-cell engagers. Market participants are focusing on improving therapeutic efficacy, safety profiles, and treatment accessibility to address evolving cancer treatment needs.

Molecular Format Insights

The bispecific T-cell engagers segment accounted for the largest revenue share, over 92.0% in 2025 and is expected to grow at the fastest CAGR during the forecast period, driven by their ability to redirect T cells toward tumor cells and trigger targeted immune responses. Expanding clinical applications across hematological malignancies and solid tumors further supported segment growth. For instance, in May 2024, the U.S. FDA granted accelerated approval to tarlatamab, a DLL3-directed CD3 T-cell engager, for extensive-stage small-cell lung cancer, highlighting the growing therapeutic potential of bispecific T-cell engagers beyond hematological malignancies.

The TCR-based T-cell engagers segment is expected to register a significant CAGR over the forecast period, driven by their ability to recognize intracellular tumor-associated antigens presented by human leukocyte antigen (HLA) molecules, thereby expanding target accessibility beyond conventional cell-surface antigens. Advancements in TCR engineering and growing clinical development of therapies targeting solid tumors are expected to support segment growth.

Target Antigen Insights

The CD19 segment dominated the market with a 31.3% share in 2025, driven by the established role of CD19 as a therapeutic target in B-cell malignancies, including non-Hodgkin lymphoma and acute lymphoblastic leukemia. The global clinical use of CD19-directed therapies, supported by ongoing research to improve treatment efficacy and address disease relapse, further contributed to segment dominance.

The CD20 segment is expected to register the fastest CAGR over the forecast period, driven by the growing development of CD20-directed T-cell engagers for B-cell non-Hodgkin lymphomas and other B-cell malignancies. Increasing clinical adoption of bispecific antibodies targeting CD20 and CD3, along with ongoing efforts to improve treatment outcomes in relapsed or refractory patients, is expected to support segment growth.

Therapeutic Application Insights

The hematological malignancies segment dominated the market with a 79.4% share in 2025, driven by the established clinical efficacy of T-cell engagers in targeting blood cancers, including leukemia, lymphoma, and multiple myeloma. Strong clinical evidence, the availability of approved therapies, and continued development of novel candidates for relapsed or refractory disease supported the segment’s leading position.

The solid tumors segment is expected to register the fastest CAGR over the forecast period, driven by increasing research into T-cell engagers targeting tumor-associated antigens and overcoming the immunosuppressive tumor microenvironment. Advancements in bispecific antibody engineering and the clinical development of candidates targeting cancers such as small-cell lung cancer are expected to expand therapeutic applications and support segment growth.

Route of Administration Insights

The intravenous segment dominated the market with a share of 61.8% in 2025, driven by its global use in administering T-cell engagers, enabling controlled dosing, precise infusion management, and close monitoring for adverse events, including cytokine release syndrome. Established clinical protocols and the availability of approved intravenous formulations further supported segment dominance.

To learn more about this report, Download Free Sample Report

The subcutaneous segment is expected to register a significant CAGR over the forecast period, driven by its potential to simplify treatment administration, reduce infusion-related resource requirements, and improve patient convenience. Growing development of subcutaneous formulations of T-cell engagers is expected to support outpatient treatment delivery and expand access to these therapies.

Regional Insights

North America dominated the T-cell engager industry, accounting for the largest revenue share of 74.1% in 2025, supported by ongoing clinical development and regulatory initiatives to advance novel immunotherapies for cancer. For instance, in October 2026, Vir Biotechnology announced that the U.S. FDA granted Fast Track designation to VIR-5500, a PSMA-targeted, dual-masked T-cell engager being developed in collaboration with Astellas Pharma for late-line metastatic castration-resistant prostate cancer. This development highlights continued efforts to advance next-generation T-cell engagers for solid tumors and address unmet treatment needs.

To learn more about this report, Download Free Sample Report

U.S. T-Cell Engager Market Trends

The T-cell engager industry in the U.S. is expected to grow over the forecast period, supported by ongoing investments in immunotherapy development and strategic acquisitions to expand therapeutic pipelines. For instance, in June 2026, UCB completed its acquisition of Candid Therapeutics, a U.S.-based biotechnology company developing T-cell engager therapies for autoimmune diseases. The transaction highlights growing industry interest in expanding T-cell engager applications beyond oncology and strengthening the pipeline of next-generation immunotherapies.

Europe T-Cell Engager Market Trends

The T-cell engager market in Europe was identified as a lucrative region in this industry, supported by regulatory authorization of novel bispecific therapies and efforts to expand treatment options for relapsed or refractory cancers. For instance, in April 2025, the European Commission authorized Lynozyfic (linvoseltamab), a BCMA × CD3 bispecific antibody, for adults with relapsed or refractory multiple myeloma. The authorization represents a market-specific milestone for the availability of another T-cell-engaging therapy in the European Union.

The UK T-cell engager market is supported by clinical research evaluating novel molecular designs to improve the safety and efficacy of immunotherapies. For instance, in March 2026, Cancer Research UK and NovalGen announced that the first patient had been dosed in a Phase I trial of NVG-222, a self-regulating ROR1 × CD3 T-cell engager for ROR1-positive blood cancers. The candidate's development highlights efforts to control excessive immune activation while maintaining antitumor activity.

The T-cell engager market in Germany is anticipated to grow significantly over the forecast period, supported by domestic biopharmaceutical companies advancing targeted immunotherapies. For instance, in April 2026, Germany-based Boehringer Ingelheim announced a clinical collaboration with Zai Lab to evaluate obrixtamig, a DLL3/CD3 T-cell engager, in combination with a DLL3-targeting antibody-drug conjugate (ADC). The Phase Ib/II study will assess the safety, tolerability, and preliminary clinical activity of the combination in patients with small-cell lung cancer and other neuroendocrine carcinomas, highlighting continued innovation in T-cell engager-based combination therapies.

Asia Pacific T-Cell Engager Market Trends

Asia-Pacific is expected to grow at the fastest CAGR of 16.6% during the forecast period, driven by the development of locally developed therapies and increasing clinical evaluation of bispecific and multispecific antibody formats. Growing clinical research activity and investments in innovative cancer immunotherapies are expected to support regional market growth. However, market adoption will depend on clinical outcomes, regulatory approvals, treatment accessibility, and reimbursement policies.

China’s T-cell engager market is supported by domestic development of next-generation multispecific antibody therapies and the advancement of locally developed candidates into clinical trials. For instance, in September 2026, China-based Biotle reported preliminary clinical findings from its Phase I/II study of BTL-101, a trispecific T-cell engager targeting BCMA, GPRC5D, and CD3 for relapsed/refractory multiple myeloma. The early findings indicate continued progress in China’s development of innovative T-cell engager therapies, although further clinical evaluation is required to establish safety and efficacy.

The T-cell engager market in Japan is expected to grow steadily, driven by advancements in antibody engineering and ongoing research into targeted cancer therapies. Increasing focus on novel antigen targets and combination treatment approaches is expected to support pipeline development. However, market growth will depend on clinical outcomes, regulatory approvals, and the commercialization of therapies for hematological malignancies and solid tumors.

Latin America T-Cell Engager Market Trends

The Latin America T-cell engager market is expected to grow gradually, supported by expanding access to advanced cancer therapies, increasing clinical research activity, and improvements in specialized oncology infrastructure. Growing participation in clinical trials and progress in regulatory approvals are expected to support the development and adoption of T-cell engager therapies across the region.

MEA T-Cell Engager Market Trends

MEA T-cell engager market is expected to grow steadily, supported by investments in healthcare infrastructure, the expansion of specialized oncology services, and increasing access to innovative cancer treatments. The development of regional clinical research capabilities and greater availability of advanced immunotherapies are expected to support the adoption of T-cell engager therapies across the region.

Key Companies & Market Share Insights

Several well-established companies operate in the T-cell engager market, supported by their portfolios of approved therapies and investigational candidates targeting hematological malignancies and solid tumors. Leading players such as Amgen Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson, Pfizer Inc., AbbVie Inc., Genmab A/S, Regeneron Pharmaceuticals Inc., Immunocore Holdings plc., LINDIS BIOTECH, Atnahs Pharma Netherlands B.V., Astellas Pharma Inc., AstraZeneca, Innovent, Wuhan YZY Biopharma Co., Ltd., and Xencor maintain their market presence through product development, clinical advancements, strategic collaborations, licensing agreements, and pipeline expansion focused on enhancing therapeutic efficacy, broadening target coverage, improving safety profiles, and advancing the commercialization of T-cell engager therapies.

Key T-cell Engager Companies:

The following key companies have been profiled for this study on the T-cell engager market include:

• Amgen Inc.

• F. Hoffmann-La Roche Ltd

• Johnson & Johnson

• Pfizer Inc.

• AbbVie Inc.

• Genmab A/S

• Regeneron Pharmaceuticals Inc.

• Immunocore Holdings plc.

• LINDIS BIOTECH

• Atnahs Pharma Netherlands B.V.

• Astellas Pharma Inc.

• AstraZeneca

• Innovent

• Wuhan YZY Biopharma Co., Ltd.

• Xencor

Recent Developments

• In June 2026, CytomX Therapeutics expanded its strategic research collaboration with Regeneron Pharmaceuticals to develop conditionally activated bispecific cancer therapies, leveraging proprietary platforms to improve therapeutic selectivity and advance next-generation T-cell engager development in the United States.

• In March 2026, Johnson & Johnson received U.S. FDA approval for Tecvayli, a bispecific T-cell engager, in combination with Darzalex Faspro for relapsed or refractory multiple myeloma, expanding treatment options and supporting market growth through broader adoption of T-cell engager therapies.

• In June 2024, AbbVie received accelerated U.S. FDA approval for EPKINLY (epcoritamab), a CD20-directed CD3 bispecific T-cell engager, for treating adults with relapsed or refractory follicular lymphoma, expanding therapeutic applications and strengthening commercial opportunities in the T-cell engager market.

Global T-cell Engager Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global T-cell engager market on the basis of molecular format, target antigen, therapeutic application, route of administration, and region

• Molecular Format Outlook (Revenue, USD Million, 2021 - 2033)

  • Bispecific T-Cell Engagers

  • TCR-Based T-Cell Engagers

• Target Antigen Outlook (Revenue, USD Million, 2021 - 2033)

  • CD19

  • CD20

  • BCMA

  • GPRC5D

  • DLL3

  • Others

• Therapeutic Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Hematological Malignancies

  • Solid Tumors

    • Small Cell Lung Cancer

    • Melanoma

    • Other Solid Tumors

• Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)

  • Intravenous

  • Subcutaneous

  • Other (Intraperitoneal)

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The T-cell engager market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each T-cell engager segment quantified using the revenue-capture definitions in the table below.

Delivered Customizations

This report has been delivered with the following In-depth customizations